Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]Befotertinib AME Study in Healthy Chinese Males
NCT04464551Phase 1Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of befotertinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Primary endpoints: Radioactivity concentration of each plasma sample, Radioactivity concentration of each urine samples and 3 more. Status: unknown.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04464551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464551.